株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ジェネリック医薬品の米国市場:産業動向、シェア、規模、成長率、機会、予測

US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

発行 IMARC Services Private Limited 商品コード 359386
出版日 ページ情報 英文 109 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.53円で換算しております。
Back to Top
ジェネリック医薬品の米国市場:産業動向、シェア、規模、成長率、機会、予測 US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024
出版日: 2019年02月11日 ページ情報: 英文 109 Pages
概要

当レポートでは、米国のジェネリック医薬品市場について調査分析し、産業概要、セグメント別の市場分析、競合情勢、規制、主要企業などについて、体系的な情報を提供しています。

第1章 序文

第2章 調査範囲・手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 米国のジェネリック医薬品が有利な理由

  • ブロックバスター薬の特許満了
  • ジェネリック医薬品と新薬の価格差
  • 政府と第三者支払人の予算削減
  • ジェネリック医薬品の調合・処方のインセンティブ
  • 償還と自己負担金の抑制
  • バイオシミラー

第6章 世界のジェネリック医薬品市場

  • 市場実績
  • 市場内訳:国別
  • 市場予測
  • 最も多く処方されているジェネリック・ブランド医薬品

第7章 米国のジェネリック医薬品市場

  • 米国の医薬品市場の実績
  • 米国のジェネリック医薬品市場の実績

第8章 市場内訳:セグメント別

  • 非ブランドのジェネリック医薬品
  • ブランドのジェネリック医薬品

第9章 市場内訳:治療分野

  • CNS
  • 心血管
  • 皮膚
  • 泌尿生殖器/ホルモン
  • 呼吸器
  • リウマチ
  • 糖尿病
  • 腫瘍
  • その他

第10章 市場内訳:ドラッグデリバリー別

  • 経口
  • 注射剤
  • 皮膚/局所
  • 吸入具

第11章 市場内訳:流通経路別

  • 小売薬局
  • 病院薬局

第12章 米国のジェネリック医薬品市場:SWOT分析

第13章 米国のジェネリック医薬品市場:バリューチェーン分析

第14章 サプライチェーンにおける価格メカニズムと利益率

第15章 ファイブフォース分析

第16章 米国のジェネリック医薬品市場:競合情勢

第17章 米国のジェネリック医薬品産業における規制

第18章 米国のジェネリック医薬品市場:主な成功要因

第19章 米国のジェネリック医薬品市場:障壁

第20章 ジェネリック医薬品製造プラント設立の要件

第21章 米国のジェネリック医薬品市場:主要企業プロファイル

  • Teva
  • Mylan
  • Actavis
  • Sandoz
  • Sun Pharma
  • Par Pharmaceuticals
  • Endo Pharmaceuticals
  • Lupin Pharmaceuticals
  • Dr Reddy's
  • Hospira
図表

List of Figures

  • Figure 1: Structure of the Pharmaceutical Industry
  • Figure 2: Classification of Generic Drugs
  • Figure 3: US: Patent Expiry Exposure (in Billion US$), 2010-2019
  • Figure 4: US: Savings from Generic Drugs (in Billion US$), 2007-2018E
  • Figure 5: Global: Generic Drug Market: Sales Value (in Billion US$), 2011-2018
  • Figure 6: Global: Generic Drug Market: Sales Volume (in Billion Standards Units), 2011-2018
  • Figure 7: Global: Generic Drug Market: Sales Value Breakup by Country (in %), 2018
  • Figure 8: Global: Generic Drug Market: Sales Volume Breakup by Country (in %), 2018
  • Figure 9: Global: Generic Drug Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 10: Global: Generic Drug Market Forecast: Sales Volume (in Billion Standards Units), 2019-2024
  • Figure 11: US: Pharmaceutical Market: Sales Volume (in Million Prescriptions), 2011-2018
  • Figure 12: US: Pharmaceutical Market: Sales Value (in Billion US$), 2011-2018
  • Figure 13: US: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2011 and 2018
  • Figure 14: US: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2011 and 2018
  • Figure 15: US: Pharmaceutical Market Forecast: Sales Volume (in Million Prescriptions), 2019-2024
  • Figure 16: US: Pharmaceutical Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 17: US: Generic Drug Market: Sales Volume (in Million Prescriptions), 2011-2018
  • Figure 18: US: Generic Drug Market: Sales Value (in Billion US$), 2011-2018
  • Figure 19: US: Generic Drug Market: Breakup by Segment (in %), 2011-2018
  • Figure 20: US: Generic Drug Market: Breakup by Therapy Area (in %), 2011-2018
  • Figure 21: US: Generic Drug Market: Breakup by Drug Delivery (in %), 2011-2018
  • Figure 22: US: Generic Drug Market: Breakup by Distribution Channel (in %), 2011-2018
  • Figure 23: US: Generic Drug Market Forecast: Sales Volume (in Million Prescriptions), 2019-2024
  • Figure 24: US: Generic Drug Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 25: Generic Drug Market: Price Structure (US$/Ton)
  • Figure 25: US: Generic Drug Market: SWOT Analysis
  • Figure 26: US: Generic Drug Market: Value Chain Analysis
  • Figure 27: US: Generic Drug Market: Pricing Mechanism and Profit Margins at the Various Levels of the Supply Chain
  • Figure 28: US: Generic Drug Market: Porter's Five Forces Analysis
  • Figure 29: US: Generic Drug Market: Unbranded Generics (in Million Prescriptions), 2011 & 2018
  • Figure 30: US: Generic Drug Market Forecast: Unbranded Generics (in Million Prescriptions), 2019-2024
  • Figure 31: US: Generic Drug Market: Branded Generics (in Million Prescriptions), 2011 & 2018
  • Figure 32: US: Generic Drug Market Forecast: Branded Generics (in Million Prescriptions), 2019-2024
  • Figure 33: US: Generic Drug Market: CNS (in Million US$), 2011 & 2018
  • Figure 34: US: Generic Drug Market Forecast: CNS (in Million US$), 2019-2024
  • Figure 35: US: Generic Drug Market: Cardiovascular (in Million US$), 2011 & 2018
  • Figure 36: US: Generic Drug Market Forecast: Cardiovascular (in Million US$), 2024
  • Figure 37: US: Generic Drug Market: Dermatology (in Million US$), 2011 & 2018
  • Figure 38: US: Generic Drug Market Forecast: Dermatology (in Million US$), 2019-2024
  • Figure 39: US: Generic Drug Market: Genitourinary/Hormonal (in Million US$), 2011 & 2018
  • Figure 40: US: Generic Drug Market Forecast: Genitourinary/Hormonal (in Million US$), 2019-2024
  • Figure 41: US: Generic Drug Market: Respiratory (in Million US$), 2011 & 2018
  • Figure 42: US: Generic Drug Market Forecast: Respiratory (in Million US$), 2019-2024
  • Figure 43: US: Generic Drug Market: Rheumatology (in Million US$), 2011 & 2018
  • Figure 44: US: Generic Drug Market Forecast: Rheumatology (in Million US$), 2019-2024
  • Figure 45: US: Generic Drug Market: Diabetes (in Million US$), 2011 & 2018
  • Figure 46: US: Generic Drug Market Forecast: Diabetes (in Million US$), 2019-2024
  • Figure 47: US: Generic Drug Market: Oncology (in Million US$), 2011 & 2018
  • Figure 48: US: Generic Drug Market Forecast: Oncology (in Million US$), 2019-2024
  • Figure 49: US: Generic Drug Market: Others (in Million US$), 2011 & 2018
  • Figure 50: US: Generic Drug Market Forecast: Others (in Million US$), 2019-2024
  • Figure 51: US: Generic Drug Market: Orals (in Million US$), 2011 & 2018
  • Figure 52: US: Generic Drug Market Forecast: Orals (in Million US$), 2019-2024
  • Figure 53: US: Generic Drug Market: Injectables (in Million US$), 2011 & 2018
  • Figure 54: US: Generic Drug Market Forecast: Injectables (in Million US$), 2019-2024
  • Figure 55: US: Generic Drug Market: Dermal/Topical (in Million US$), 2011 & 2018
  • Figure 56: US: Generic Drug Market Forecast: Dermal/Topical (in Million US$), 2019-2024
  • Figure 57: US: Generic Drug Market: Inhalers (in Million US$), 2011 & 2018
  • Figure 58: US: Generic Drug Market Forecast: Inhalers (in Million US$), 2019-2024
  • Figure 59 US: Generic Drug Market: Retail Pharmacies (in Million US$), 2011 & 2018
  • Figure 60: US: Generic Drug Market Forecast: Retail Pharmacies (in Million US$), 2019-2024
  • Figure 61: US: Generic Drug Market: Hospital Pharmacies (in Million US$), 2011 & 2018
  • Figure 62: US: Generic Drug Market Forecast: Hospital Pharmacies (in Million US$), 2019-2024
  • Figure 63: US: Generic Drug Market: Sales Breakup of Top Players (in %), 2018
  • Figure 64: US: Generic Drug Market: Volume Share of Top Players (in %), 2018
  • Figure 65: US: Generic Drug Market: Volume Share by Distribution (in %), 2018
  • Figure 66: US: Generic Drug Prices as a Percentage of Branded Drug Prices - Based on Number of Competitors
  • Figure 67: US: Generic Drug Market: Detailed Process Flow
  • Figure 68: US: Generic Drug Market: Raw Material Requirements
  • Figure 69: US: Generic Drug Market: Plant Layout
  • Figure 70: US: Generic Drug Market: Packaging Requirements

List of Tables

  • Table 1: US: Sales and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$)
  • Table 2: US: Expenses of Generic and Branded Drug Manufacturers (in %)
  • Table 3: Global: Generic Drug Market: Volume Performance of Top Generic Drugs (in Million Prescriptions)
  • Table 4: Global: Branded Drug Market: Volume Performance of Top Branded Drugs (in Million Prescriptions)
  • Table 5: US: Generic Drug Market: Sales Performance of Top Players (in Billion US$), 2018
  • Table 6: US: Generic Drug Market: Volume Performance of Top Players (in Billion Units), 2018
  • Table 7: US: Generics Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2018
  • Table 8: US: Overview of Pharmaceutical Regulations
  • Table 9: US: Generic Drug Market: Land and Construction Requirements
  • Table 10: US: Generic Drug Market: Machinery and Infrastructure Requirements
  • Table 11: US: Generic Drug Market: Utility Requirements
  • Table 12: US: Generic Drug Market: Manpower Requirements
目次
Product Code: SR1018G45_Report

The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the majority of the total prescriptions dispensed in the United States. During 2011-2018, the US generic drug market grew at a CAGR of 12% and currently represents a multibillion dollar industry. The biggest catalyst of this industry is the significantly lower price of generics compared to branded drugs. Although generics are chemically identical to their branded counterparts, they are typically sold at substantial discounts from the branded price. This has enabled governments and third-party payers to save billions of dollars in healthcare expenditures and resulted in lower copayments for patients. Other factors such as patent expiration of blockbuster innovator drugs, ageing population and an increasing prevalence of chronic diseases have also acted as catalysts for this market.

The report entitled "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" provides a comprehensive insight into the historical and current trends as well as the future prospects of the generic drug market in the United States. This study serves as an exceptional tool to understand the sales trends, volume trends, growth, key segments, competitive structure, regulations, major manufacturer, major distributors, top drugs, manufacturing requirements, opportunities and future prospects of the US generic drug market. This report can serve as an excellent guide for manufacturers, consultants, researchers, marketing strategists and all those who plan to foray into the US generic drug market in any form.

Key Questions Answered in This Report:

  • Historical, current and future sales trends in the US generic drug market?
  • Historical, current and future prescription trends in the US generic drug market?
  • Performance of the US generic drug market compared to the US pharmaceutical market?
  • Performance of the US generic drug market compared to other major generic drug markets?
  • Structure of the US generic drug market?
  • Market Breakup by Therapy Area?
  • Market Breakup by Drug Delivery?
  • Market Breakup by Distribution Channel?
  • Competitive landscape in the US generic drug market?
  • Top US generic drug manufacturers and their market shares?
  • Distribution of generic drugs in the US?
  • Top US generic drug distributors and their market shares?
  • Most prescribed generic drugs in the US?
  • Pricing analysis of generic drugs?
  • Value chain analysis of generic drugs in the US?
  • Regulations in the US generic drug market?
  • Manufacturing process of generic drugs?
  • Machinery and raw material requirements for manufacturing generic drugs?
  • Key success and risk factors in the US generic drug market?

Table of Contents

1. Preface

2. Scope and Methodology

  • 2.1. Objectives of the Study
  • 2.2. Stakeholders
  • 2.3. Data Sources
    • 2.3.1. Primary Sources
    • 2.3.2. Secondary Sources
  • 2.4. Market Estimation
    • 2.4.1. Bottom-Up Approach
    • 2.4.2. Top-Down Approach
  • 2.5. Forecasting Methodology

3. Executive Summary

4. US Generic Drug Market - Introduction

  • 4.1. What are Generic Drugs?
  • 4.2. Unbranded and Branded Generics
  • 4.3. Authorized Generics
  • 4.4. Commoditized and Specialty Generics

5. Why is the US Generic Drug Market So Lucrative

  • 5.1. Patent Expiry of Blockbuster Drugs
  • 5.2. Significant Price Differential between Generics and Innovator Drugs
  • 5.3. Savings for the Government and Third-Party Payers
  • 5.4. Incentives for Dispensing and Prescribing Generic Drugs
  • 5.5. Reimbursement and Lower Co-payments
  • 5.6. Biosimilars

6. Global Generic Drug Market

  • 6.1. Market Performance
    • 6.1.1. Volume Trends
    • 6.1.2. Value Trends
  • 6.2. Market Breakup by Country
  • 6.3. Market Forecast
  • 6.4. Most Prescribed Generic and Branded Drugs

7. US Generic Drug Market

  • 7.1. US Pharmaceutical Market Performance
    • 7.1.1. Volume Trends
    • 7.1.2. Value Trends
    • 7.1.3. Market Breakup by Type
    • 7.1.4. Market Forecast
  • 7.2. US Generic Drug Market Performance
    • 7.2.1. Volume Trends
    • 7.2.2. Value Trends
    • 7.2.3. Market Breakup by Segment
    • 7.2.4. Market Breakup by Therapy Area
    • 7.2.5. Market Breakup by Drug Delivery
    • 7.2.6. Market Breakup by Distribution Channel
    • 7.2.7. Market Forecast

8. Market Breakup by Segment

  • 8.1. Unbranded Generics
    • 8.1.1. Market Trends
    • 8.1.2. Market Forecast
  • 8.2. Branded Generics
    • 8.2.1. Market Trends
    • 8.2.2. Market Forecast

9. Market Breakup by Therapy Area

  • 9.1. CNS
    • 9.1.1. Market Trends
    • 9.1.2. Market Forecast
  • 9.2. Cardiovascular
    • 9.2.1. Market Trends
    • 9.2.2. Market Forecast
  • 9.3. Dermatology
    • 9.3.1. Market Trends
    • 9.3.2. Market Forecast
  • 9.4. Genitourinary/Hormonal
    • 9.4.1. Market Trends
    • 9.4.2. Market Forecast
  • 9.5. Respiratory
    • 9.5.1. Market Trends
    • 9.5.2. Market Forecast
  • 9.6. Rheumatology
    • 9.6.1. Market Trends
    • 9.6.2. Market Forecast
  • 9.7. Diabetes
    • 9.7.1. Market Trends
    • 9.7.2. Market Forecast
  • 9.8. Oncology
    • 9.8.1. Market Trends
    • 9.8.2. Market Forecast
  • 9.9. Others
    • 9.9.1. Market Trends
    • 9.9.2. Market Forecast

10. Market Breakup by Drug Delivery

  • 10.1. Oral
    • 10.1.1. Market Trends
    • 10.1.2. Market Forecast
  • 10.2. Injectables
    • 10.2.1. Market Trends
    • 10.2.2. Market Forecast
  • 10.3. Dermal/Topical
    • 10.3.1. Market Trends
    • 10.3.2. Market Forecast
  • 10.4. Inhalers
    • 10.4.1. Market Trends
    • 10.4.2. Market Forecast

11. Market Breakup by Distribution Channel

  • 11.1. Retail Pharmacies
    • 11.1.1. Market Trends
    • 11.1.2. Market Forecast
  • 11.2. Hospital Pharmacies
    • 11.2.1. Market Trends
    • 11.2.2. Market Forecast

12. US Generic Drug Market - SWOT Analysis

  • 12.1. Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats

13. US Generic Drug Market - Value Chain Analysis

  • 13.1. Research and Development
  • 13.2. Raw Material Procurement
  • 13.3. Manufacturing
  • 13.4. Marketing
  • 13.5. Distribution

14. Pricing Mechanism and Profit Margins at Various Levels of the Supply Chain

15. Porter's Five Forces Analysis

  • 15.1. Overview
  • 15.2. Bargaining Power of Buyers
  • 15.3. Bargaining Power of Suppliers
  • 15.4. Degree of Rivalry
  • 15.5. Threat of New Entrants
  • 15.6. Threat of Substitutes

16. US Generic Drug Market- Competitive Landscape

  • 16.1. US Generic Drug Market - Competitive Structure
  • 16.2. US Generic Drug Market - Breakup of Key Players
  • 16.4. US Generic Drug Market - Most Prescribed Generic Drugs
  • 16.5. US Generic Drug Market - Market Breakup by Distribution
  • 16.6. US Generic Drug Market - Pricing Dynamics

17. Regulations in the US Generic Drug Industry

  • 17.1. Overview of Pharmaceutical Regulations
  • 17.2. Drug Applications
  • 17.3. Patents and Market Exclusivity
  • 17.4. Regulatory Requirements for Generic Drugs
  • 17.5. The Hatch-Waxman Act
  • 17.6. Certifications
  • 17.7. Other Important Considerations

18. US Generic Drug Market: Key Success Factors

19. US Generic Drug Market: Road Blocks

20. Requirements for Setting Up a Generic Drug Manufacturing Plant

  • 20.1. Manufacturing Process
  • 20.2. Raw Material Requirements
  • 20.3. Raw Materials Pictures
  • 20.4. Land and Construction Requirements
  • 20.5. Machinery and Infrastructure Requirements
  • 20.6. Machinery Pictures
  • 20.7. Plant Layout
  • 20.8. Packaging Requirements
  • 20.9. Utility Requirements
  • 20.10. Manpower Requirements

21. US Generic Drug Market - Key Company Profiles

  • 21.1. Teva
  • 21.2. Mylan
  • 21.3. Actavis
  • 21.4. Sandoz
  • 21.5. Sun Pharma
  • 21.6. Par Pharmaceuticals
  • 21.7. Endo Pharmaceuticals
  • 21.8. Lupin Pharmaceuticals
  • 21.9. Dr Reddy's
  • 21.10. Hospira
Back to Top